UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
___________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2023
___________________________
(Exact name of registrant as specified in its charter)
___________________________
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of principal executive offices) | (zip code) | |||||||
Registrant’s telephone number, including area code: (919) 213-9835
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 15, 2023, G1 Therapeutics, Inc. (the “Company”) held its 2023 annual meeting of stockholders. At the meeting, the stockholders: (1) re-elected each of Garry A. Nicholson, Mark A. Velleca, M.D., Ph.D., and Glenn P. Muir to the Company’s Board of Directors, each as a Class III director for a term of three years to serve until the 2026 annual meeting of stockholders or until their respective successors have been elected and qualified or until their respective earlier death, resignation or removal (the “Election of Directors”); (2) approved, on a non-binding, advisory basis, compensation awarded or paid to the Company’s named executive officers for the fiscal year of 2022 (the “Advisory Vote on the Compensation of Our Named Executive Officers”); and (3) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (the “Ratification of Appointment of Independent Registered Public Accounting Firm”). A more complete description of these matters is set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2023.
The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker nonvotes on each of the foregoing matters are set forth below.
1. Election of Directors
Nominee | Shares Voted For | Shares Voted to Withhold Authority | Broker Nonvotes | |||||||||||||||||
Garry A. Nicholson | 13,303,821 | 7,546,284 | 14,486,827 | |||||||||||||||||
Mark A. Velleca, M.D., Ph.D. | 15,841,462 | 5,008,643 | 14,486,827 | |||||||||||||||||
Glenn P. Muir | 20,436,044 | 414,061 | 14,486,827 | |||||||||||||||||
2. Advisory Vote on the Compensation of Our Named Executive Officers
Shares Voted For | Shares Voted Against | Shares Abstaining | Broker Nonvotes | |||||||||||||||||
14,070,123 | 2,379,219 | 4,400,763 | 14,486,827 | |||||||||||||||||
3. Ratification of Appointment of Independent Registered Public Accounting Firm
Shares Voted For | Shares Voted Against | Shares Abstaining | ||||||||||||
35,063,659 | 195,724 | 77,549 | ||||||||||||
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
| Exhibit No. | Description | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| G1 THERAPEUTICS, INC. | ||||||||
| By: | /s/ Monica Roberts Thomas | |||||||
| Monica Roberts Thomas | ||||||||
| General Counsel | ||||||||
Date: June 16, 2023 | ||||||||